Immunomedics Inc
IMMU
IMMU was delisted on the 22nd of October, 2020.
204 hedge funds and large institutions have $3.37B invested in Immunomedics Inc in 2019 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 73 increasing their positions, 55 reducing their positions, and 49 closing their positions.
285% more call options, than puts
Call options by funds: $68.1M | Put options by funds: $17.7M
46% more capital invested
Capital invested by funds: $2.3B → $3.37B (+$1.07B)
38% more funds holding in top 10
Funds holding in top 10: 8 → 11 (+3)
33% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 55
0% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 49
0% less funds holding
Funds holding: 205 → 204 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$236M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$47.5M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
+$37.2M |
| 4 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$33.4M |
| 5 |
DM
Deerfield Management
New York
|
+$31.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$59.7M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$43.1M |
| 3 |
Millennium Management
New York
|
-$38.9M |
| 4 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$33.3M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$24.7M |
IMMU Hedge Fund Activity: Q1 2019 in Review
204 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Immunomedics Inc (IMMU) for Q1 2019, worth a combined $3.37B — up 46% from $2.3B a quarter earlier.
Fund positioning in IMMU was balanced in Q1 2019: 49 funds opened new positions, 49 closed out, 73 added to existing stakes and 55 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $236M. The largest seller was T. Rowe Price Associates, cutting an estimated $59.7M.
- 204 institutional investors held Immunomedics Inc (IMMU) as of Q1 2019, down from 205 in Q4 2018.
- Funds reported $3.37B of Immunomedics Inc stock for Q1 2019, up 46% quarter-over-quarter.
- 49 funds opened new Immunomedics Inc positions in Q1 2019 and 49 closed out, a net change of 0 holders.
- The largest Immunomedics Inc buyer in Q1 2019 was Fidelity Investments, an estimated $236M added.
- The largest Immunomedics Inc seller in Q1 2019 was T. Rowe Price Associates, an estimated $59.7M sold.
Based on aggregated 13F filings for Q1 2019.